

Product datasheet for **TL315022V**

SUR1 (ABCC8) Human shRNA Lentiviral Particle (Locus ID 6833)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	SUR1 (ABCC8) Human shRNA Lentiviral Particle (Locus ID 6833)
Locus ID:	6833
Synonyms:	ABC36; HHF1; HI; HRINS; MRP8; PHHI; PNDM3; SUR; SUR1; SUR1delta2; TNDM2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ABCC8 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_000352 , NM_001287174 , NM_001351295 , NM_001351296 , NM_001351297 , NR_147094 , NM_000352.1 , NM_000352.2 , NM_000352.3 , NM_000352.4 , NM_001287174.1 , BC167829 , BM313666 , BM352492 , NM_001287174.2 , NM_000352.6
UniProt ID:	Q09428
Summary:	The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MRP subfamily which is involved in multi-drug resistance. This protein functions as a modulator of ATP-sensitive potassium channels and insulin release. Mutations in the ABCC8 gene and deficiencies in the encoded protein have been observed in patients with hyperinsulinemic hypoglycemia of infancy, an autosomal recessive disorder of unregulated and high insulin secretion. Mutations have also been associated with non-insulin-dependent diabetes mellitus type II, an autosomal dominant disease of defective insulin secretion. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online >](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).